HC Andersen Capital Certified Adviser Portal by HC Andersen Capital HC Andersen Capital

This portal is for the companies HCA acts as Certified Adviser for

Please reach out to HCA if you have not received the code.

Welcome to HCA’s Certified Adviser Client Portal

The working reference for the companies HCA acts as Certified Adviser for

This area is reserved for companies for which HC Andersen Capital acts as Certified Adviser on Nasdaq First North Growth Market Denmark. It brings together news, guidance and contact details in one place, kept current as the rules change.

What you will find here

Compliance and regulation
Practical guidance on the disclosure obligations that apply to First North issuers, written around the situations that typically arise: financial reports, capital raises, warrant grants, share buybacks and manager’s transactions.
Regulatory news
What is changing, and when, under News.
Relevant links
Links to relevant regulation and guidelines from the Danish FSA, Nasdaq and others, under Links.
Tools and resources
A closed period calculator that allows for your internal rules, and a delay decision record. Nothing you type is saved or sent anywhere.
Your Certified Adviser team
Named contacts at HCA and how to reach them, under Advisers.

Two things worth knowing before you start

Hovering a term like MAR, or a citation like Article 17(4), opens a short definition with a link to the section that explains it properly. And the search box in the menu searches the full text of every section, not just the headings, so if you half remember a phrase you can find it that way.

Where to start

The two rule sets

MAR, the Nasdaq First North Rulebook, and the announcement categories

As a company admitted to trading on Nasdaq First North Growth Market Denmark, your disclosure obligations come from two sources that operate side by side.

The Market Abuse Regulation

MAR (Regulation (EU) No 596/2014) is a directly applicable EU regulation. It is not a regulation that Nasdaq administers and it is not a regulation you can contract out of. Its core obligation for issuers is Article 17: inside information directly concerning you must be disclosed to the market as soon as possible. As soon as possible means immediately upon the information meeting the Article 7 threshold, subject only to the minimum time needed to verify and formulate an accurate announcement. MAR applies identically to First North and to the Main Market, and draws no distinction based on the type of trading venue. Where First North issuers do get relief, it is narrow and specific, such as the simplified insider list regime under Article 18(6).

The Nasdaq First North Growth Market Rulebook

The Rulebook adds obligations of its own: a periodic reporting timetable, a published financial calendar, and a list of specific decisions and events that must be disclosed whether or not they amount to inside information. That list covers changes to share capital, resolutions of the general meeting, changes in board, management or Certified Adviser, decisions on warrant and option programmes, and the obligation to correct previously disclosed information that turns out to be wrong.

These two sets of obligations are cumulative. Meeting the Rulebook's reporting timetable does not suspend the continuous MAR obligation, and a Rulebook-driven announcement does not become optional because the information falls short of the inside information threshold. In practice, most events covered in this portal are disclosable under one regime, the other, or both, and each section below says which.

Announcement categories, English and Danish names

Every company announcement is published under a Nasdaq category. Choosing the right one matters: the category is how the market, data vendors and the Danish FSA identify what kind of information you are releasing, and a misfiled inside information announcement is a disclosure mistake. Nasdaq revised the category names in 2025. The table below maps the Rulebook provision to the current English name and to the Danish name you select when publishing via Copenhagen. The only information that also has to be reported to the Danish FSA (Finanstilsynet) is Managers’ Transactions and delayed inside information.

Nasdaq RulebookNasdaq category (English)Nasdaq category (Danish, CPH)Reporting to the Danish FSA
3.4.1Company description / prospectusVirksomhedsbeskrivelse / prospectNo
4.1Inside informationIntern videnNo, only delayed inside information
Not applicableTender offerOvertagelsestilbudNo
4.2.4, 4.2.6, 4.2.7Other information disclosed according to the rules of the ExchangeAndre oplysningsforpligtelser offentliggjort efter børsens reglerNo
4.2.2(a)Notice to general meetingIndkaldelse til generalforsamlingNo
4.2.2(b)Decisions of general meetingForløb af generalforsamlingNo
4.2.3Changes in board / management / certified adviser / auditor / liquidity providerÆndring i ledelse / revision / certified adviser / liquidity providerNo
4.2.5Total number of voting rights and capitalAntal stemmerettigheder og kapitalNo
Suppl. D, 4.3.1Annual financial reportÅrsrapportNo
Suppl. D, 4.3.2Financial statement releaseÅrsregnskabsmeddelelseNo
Suppl. D, 4.3.1Half year financial reportHalvårsrapportNo
Suppl. D, 4.3.2Interim report (Q1 and Q3)Delårsrapport / Periodemeddelelse (Q1 og Q3)No
4.5Financial calendarFinanskalenderNo
MAR art. 19Managers' TransactionsLedende medarbejderes transaktionerYes, Managers’ Transactions / Ledende medarbejderes og nærtståendes transaktioner

Inside information under MAR

MAR Articles 7, 17 and 18

Inside information sits at the centre of your continuous disclosure obligations. Getting the analysis right, meaning what qualifies, how it must be handled internally, and when publication may lawfully be delayed, is one of the most complicated compliance judgments a listed company makes.

What qualifies as inside information

Article 7(1)(a) MAR defines inside information as information of a precise nature which has not been made public, relating directly or indirectly to one or more issuers or financial instruments, and which, if made public, would be likely to have a significant effect on the price. Four criteria must all be met.

Precise
The information indicates circumstances that exist or may reasonably be expected to come into existence, or an event that has occurred or may reasonably be expected to occur and is specific enough to allow a conclusion about the likely price effect.
Not made public
It has not been disclosed in a way that gives the market fast access and allows complete, correct and timely assessment.
Relates to the issuer or the instrument
Directly or indirectly. This covers information generated inside the company as well as external information about it.
Price-sensitive
A reasonable investor would be likely to use it as part of the basis of an investment decision, known as the reasonable investor test.

Three main types of inside information

Inside information may arise gradually over time or immediately as a fact.

Decision-dependent inside information
Inside information that arises as a fact when a specific decision is made, for example a strategy or other material decision entailing a choice between different paths.
External events
Information that does not directly concern the company but is published or communicated to it, for example competitor matters, shareholder matters, or a chair or CEO deciding to step down. The inside information arises either as uncertain inside information, where the impact is still uncertain, or directly as a fact.
Stage-based inside information (protracted processes)
Protracted processes, for example M&A processes, new products or major agreements, where information arises as uncertain inside information and where the probability of successful completion typically increases over time.

The disclosure obligation

Under Article 17(1) you must inform the public as soon as possible when inside information has materialised as a fact and is 100% certain, by company announcement in the category Inside information. As soon as possible means without delay once the information exists and the criteria are met, subject only to the minimum time needed to verify and formulate an accurate announcement. It does not mean at the next convenient point in your reporting cycle, or when the board meets next time.

How the announcement must be made

In its capital markets newsletter of 27 June 2025, the Danish FSA stressed that issuers must meet the formal requirements for the method of publication, set out in Commission Implementing Regulation (EU) 2016/1055. Under Article 2(1)(b), the communication must state:

  • that the information communicated is inside information;
  • the identity of the issuer, meaning the full official name;
  • the identity of the person submitting the notification, with first name, surname and position within the issuer;
  • the subject matter of the inside information; and
  • the date and time of the communication to the media. Nasdaq will automatically time stamp releases.

Under Article 3 of the same regulation, disclosed inside information must be kept easily accessible on your website in chronological order. See Information on the website.

Handling uncertain inside information before it is disclosed

Until the information is disclosed, or ceases to be inside information, you must actively control its circulation.

Insider lists (Article 18)
Everyone with access must be entered on an insider list, informed in writing of their obligations and the sanctions for insider dealing and unlawful disclosure, and asked to acknowledge this.
The First North simplification (Article 18(6))
As an issuer on an SME growth market, you need only maintain a permanent insider list of the persons who have regular access to inside information by virtue of their function, typically the board, executive management and trusted staff. Main Market issuers must additionally maintain deal-specific lists. This is a genuine substantive relief, but it does not reduce the obligation to inform and to document acknowledgement.
Need-to-know access
Restrict access to those who need the information to do their job, with information barriers, secure channels and NDAs where relevant.
No selective disclosure
Briefing analysts, investors or counterparties on inside information outside the normal exercise of employment, profession or duties is unlawful disclosure, regardless of intent.
PDMR closed periods
Managers may not trade in the 30 calendar days before a half-year or year-end report under Article 19(11). Related, but a separate obligation. See Managers' transactions.

Delaying disclosure under Article 17(4)

You may delay disclosure on your own responsibility, provided all of the following three conditions are met and remain met.

  1. Legitimate interest

    Immediate disclosure would be likely to prejudice your legitimate interests. ESMA's guidelines give a non-exhaustive list, and ongoing negotiations are the classic example.

  2. Not inconsistent with prior communication

    Since 5 June 2026 the Listing Act has reformulated the condition that “the information must not be likely to mislead the public” to: the withheld information must not be inconsistent with what you have already told the market on the same matter.

  3. Confidentiality can be ensured

    You must be able to keep the information confidential, monitor actively for leaks, and disclose immediately if confidentiality is lost.

A delay decision relates to situations after the inside information has become a fact. If one of the three conditions ceases to be met, you must disclose the information as soon as possible. The delay ends when the condition ends, not when the process ends.

When the information is eventually disclosed, you must notify the Danish FSA without delay that disclosure was delayed. Under the Danish approach you are not required to submit a written explanation of the legitimate interest unless the FSA asks for it, but you should document your reasoning contemporaneously, because that is the record you will rely on if asked. The delay regime applies equally to First North and Main Market issuers. The Danish FSA’s notification form is available in Danish and English.

Protracted processes, and what changed on 5 June 2026

A protracted process develops in stages towards an outcome, such as a negotiation, a restructuring or a multi-step transaction. Under the regime up to 5 June 2026, each intermediate step could independently qualify as inside information if it met the four Article 7 criteria in its own right, which forced issuers to assess and often disclose, or formally delay, at every stage.

Since 5 June 2026 the Listing Act (Regulation (EU) 2024/2809) has amended Article 17 so that intermediate steps in a protracted process no longer need to be treated as separately disclosable. The disclosure obligation attaches to the final event or circumstance. This is a material simplification, but note two things. The insider dealing prohibitions still bite on intermediate-step information, so insider lists and confidentiality controls remain fully in force throughout the process. And the change does not affect Rulebook-driven obligations that attach to specific decisions along the way.

As a consequence of the amendment to Article 17, delayed disclosure applies only to situations where the inside information has already turned into a fact, meaning that the disclosure obligation has arisen.

Market soundings

MAR Articles 10 and 11, Delegated Regulation (EU) 2016/960 and Implementing Regulation (EU) 2016/959

A market sounding is a contact with one or more potential investors before a transaction is announced, to gauge their interest in it and in its terms, such as size, price and structure. In practice it is often called wall-crossing an investor.

Article 11 MAR protects the disclosure: when its procedure is followed, sharing inside information in a sounding is deemed lawful. Since the Listing Act the procedure is voluntary, but two of its requirements apply in every case. Where you take part in a sale of the company itself, Article 11 covers only part of the process, as the second half of this page explains.

The safe harbour procedure

Prior assessment, in every case
Before the sounding, the disclosing market participant assesses whether the information is inside information, and documents the assessment.
Consent
The investor agrees to receive inside information.
Notice to the investor
The investor is told that they may not trade on the information and must keep it confidential.
Records
Every contact, its time and what was disclosed are recorded, and the records are kept for at least five years.
Cleansing, in every case
The investor is told when the information ceases to be inside information. No notice is needed if the information has been made public.

What the Listing Act changed

  • The procedure is voluntary. A sounding that does not follow it is not automatically unlawful, but the disclosure is then assessed under the general rule in Article 10.
  • Two requirements always apply. The inside information assessment and the cleansing notice are not optional.
  • A wider definition. Soundings are covered even when no transaction follows.

Who can use the rules

Not only the issuer. Sellers of large share blocks, emission allowance market participants, third parties acting on their behalf, and bidders in a takeover or merger can use them too.

Disclosing market participantNotes
The issuer, Article 11(1)(a)Companies with instruments on a regulated market or an MTF, including Nasdaq First North, an SME growth market.
A seller in a secondary offering, Article 11(1)(b)For example a major shareholder selling a block that differs from ordinary trading, by a sales method based on a prior assessment of interest.
An emission allowance market participant, Article 11(1)(c)Not covered further here
A third party acting for any of the above, Article 11(1)(d)Typically banks, brokers, investment advisers and the Certified Adviser.
A bidder in a takeover or merger, Article 11(2)Disclosure to the holders of the securities, where the information is necessary for them to form a view, and their willingness to sell is reasonably necessary for the decision to make the offer or merge.

The recipients are potential investors, such as institutional investors, existing major shareholders and cornerstone investors. Sharing information with your own advisers is not a market sounding, and is assessed under Article 10.

Transactions where you can use a market sounding

TransactionExamples
Offering of new sharesDirected issues and private placements, including accelerated bookbuilds. Rights issues, to sound out underwriting and pre-commitments. A listing by way of dual listing, or where you already have instruments admitted to trading.
Debt and hybrid instrumentsBond issues, tap issues, convertible bonds and warrants.
Capital raising for other transactionsFinancing an acquisition.
Merger or takeoverWhere you are the bidder or a party to the merger yourself, under Article 11(2).

If the transaction is inside information, disclosure will typically have to be delayed under Article 17(4), and the people involved go on the insider list under Article 18. If confidentiality is lost, disclose immediately. See Inside information under MAR.

When the company itself is being sold

A buyer may take over the company by buying large blocks from the major shareholders, possibly combined with a capital increase. If you take part in that process, the market sounding rules cover only part of it. Giving the buyer access to due diligence is not a market sounding, and has to be lawful under Article 10 instead. Each disclosure of inside information has to be assessed on its own, and the rules on insider dealing, disclosure, takeovers and company law apply at the same time.

Who discloses what in a sale

DisclosureLegal basisIn practice
You to the buyer, in due diligenceNot a market sounding. Lawful under Article 10 if strictly necessary and proportionate, per the EU Court of Justice in Grøngaard and Bang, C-384/02.A board resolution that access is in the company’s interest. A confidentiality and standstill agreement. Only the information needed. The buyer on your insider list or its own.
You to investors in the capital increaseA market sounding, with you as the disclosing market participant under Article 11(1)(a).Follow the procedure in Article 11 and Delegated Regulation (EU) 2016/960.
Selling shareholders to buyers of share blocksA market sounding, with the sellers as disclosing market participants under Article 11(1)(b). You, or a bank, acting on their behalf are covered by Article 11(1)(d).Agree who discloses what, and keep the records accordingly.
The buyer to the other shareholdersArticle 11(2), takeover and merger, if the buyer will gain control.Covers the buyer’s approaches, not your information to the buyer.

Insider dealing in a sale

The buyer
Using inside information from due diligence to complete the takeover or merger itself is not insider dealing, under Article 9(4). The condition is that the information has been made public, or has ceased to be inside information, by the time of approval or acceptance. It does not cover buying shares in the market on the side, which is why the standstill matters.
Selling major shareholders
They may not trade on inside information, under Articles 8 and 14. Under established practice, an agreed trade between parties who hold the same information can be lawful. Make sure the information is disclosed or cleansed by completion at the latest.
PDMRs
No trading in the 30 calendar days before an interim or year-end report, under Article 19(11), and their own transactions are notified under Article 19. See Managers' transactions.

Disclosure under Article 17

  • A negotiated sale of the company will typically be inside information early in the process.
  • You decide to delay disclosure under Article 17(4). The legitimate interest is typically that disclosure would harm the negotiations, and confidentiality must be ensured. Document the decision, for example in the Delay decision record.
  • Since 5 June 2026, under the Listing Act, intermediate steps in a protracted process need not be disclosed, only the final event. The insider dealing prohibitions and insider lists still apply.
  • If the information leaks, or rumours reach the market, disclose immediately.

Takeover rules

MarketConsequence
Regulated market (Main Market)Control, normally at least one third of the voting rights, triggers a mandatory takeover offer under the Danish Capital Markets Act. The board must give its view on the offer, and competing bidders are as a rule treated equally.
First NorthThe statutory rules on mandatory offers do not apply. Check the First North rules and your articles of association.
BothNew shares from a capital increase directed at the buyer count towards the control threshold.

Company law and the prospectus

Equal treatment
The general clause in § 108 of the Danish Companies Act: no decisions that give certain shareholders an undue advantage. Any costs and resources the company spends on the sale must be justified by its own interest.
Directed issue
As a rule at market price, by board resolution under an authorisation. A discount to the buyer normally requires a general meeting resolution with a qualified majority.
Prospectus
Assess whether a prospectus is required, and the exemptions in the Prospectus Regulation, which the Listing Act widened for new shares fungible with those already admitted to trading. See Prospectus requirements.

Recommended sequence

  1. Board resolution

    To start the process, justified by the company’s interest, together with the decision to delay disclosure.

  2. Confidentiality and standstill agreement

    Signed with the buyer before it gets access to due diligence.

  3. Need-to-know access

    Limit who sees what, and keep the insider lists up to date as the process runs.

  4. Market sounding procedure

    For approaches about the capital increase and the share blocks. It is voluntary, but it is the best evidence that the disclosure was lawful.

  5. Disclosure or cleansing plan

    Plan how the information is disclosed or cleansed, by completion at the latest.

  6. Takeover rules, company law and prospectus

    Clarify which takeover rules apply, which company law resolutions are needed, and whether a prospectus is required.

  7. Bring HCA in early

    As your Certified Adviser, HCA should be involved from the start of the process, not when the announcement is due.

Financial reports

Rulebook Supplement D, MAR Articles 17 and 19(11)

Periodic reporting is where the Rulebook and MAR interact most often, and where the most common mistake is made: treating the report as the place to disclose news that arose weeks earlier.

Financial calendar

The Rulebook requires issuers to publish a financial calendar on their website ahead of the start of each financial year, setting out the dates of forthcoming financial reports, meaning the annual report, the half-year report and, where applicable, any interim management statements, quarterly reports or trading updates the company has chosen to publish, as well as other key recurring events such as the annual general meeting. Note that the financial calendar should include all planned quarterly releases, even where these are not full quarterly reports.

Once published, the dates in the calendar can be freely changed up until 14 days before the relevant event, without any separate disclosure obligation attached to the change itself. Within 14 days of the event a change is still permitted, but the company must publish a company announcement stating the new date and the reason for the change. This graduated approach reflects the market's increasing reliance on the calendar as the relevant date approaches: a change far in advance is routine administration, while a late change is itself information the market should be told about, together with the reason for it.

Issuers should therefore treat the last two weeks before any calendared event as a point of no free movement. Any date change from that point on needs to be accompanied by a reasoned announcement, not simply an updated calendar entry.

Financial reports must not be used to disclose inside information

A scheduled annual or half-year report is not the appropriate vehicle for disclosing inside information that has arisen and crystallised before the report's publication date. If, during the reporting period, the company becomes aware of information that meets the MAR Article 17 threshold, for example a material deviation from previously communicated guidance, a significant contract loss or win, or a material impairment, that information must be:

  • disclosed separately, by way of its own company announcement, as soon as possible after the obligation to disclose arises, subject only to a valid and actively monitored delay under MAR Article 17(4) where the conditions for delay are met; and
  • disclosed in advance of the periodic financial report. The company cannot simply wait and let the figures speak for themselves when the report is published.

In other words, the periodic report presents the company's full financial position and results for the period, but it must not be the first moment at which the market learns of inside information that existed earlier. Doing so would breach the as soon as possible standard in Article 17 regardless of the fact that a report was already scheduled.

Change in guidance outside the previously announced range

Where you rely on a delay under Article 17(4), one of the cumulative conditions is that the delay must not mislead the public. Since 5 June 2026 that condition is framed as the withheld information not being inconsistent with your existing public communication on the matter. This bites hardest just before a report. If you have given guidance, a trading update or any public statement on revenue or margin expectations, and the actual position now falls outside what you told the market, delay is not available.

The practical consequence: new guidance, and any change to previously published guidance that falls outside the guided range, must be published immediately. The same applies to changes in long-term financial targets.

Preliminary figures ahead of a report

Where a company chooses to publish preliminary key figures ahead of the underlying full periodic report, for example preliminary revenue or other KPIs ahead of the annual report, half-year report or a quarterly update, the announcement should be filed under the disclosure category that corresponds to what the preliminary figures actually are.

  • Preliminary headline figures ahead of the annual report, filed as Financial statement release / Årsregnskabsmeddelelse.
  • Preliminary figures ahead of a half-year report or a voluntary quarterly update, meaning an interim report for Q1 or Q3, filed under the same category as the report they precede.

Closed periods ahead of financial reports

Under Article 19(11), a PDMR must not trade in your shares or debt instruments, on their own account or for a third party, directly or indirectly, during the 30 calendar days before the announcement of a half-year or year-end report that you are obliged to publish.

Voluntary Q1 and Q3 reports

Many First North companies choose to publish interim management statements or quarterly reports for Q1 and Q3, even though the Rulebook does not require this. Strictly read, Article 19(11) only applies where the report is one the issuer is obliged to make public, so a purely voluntary quarterly update, published on an ad hoc basis with no fixed commitment, does not automatically trigger the statutory closed period.

The position changes, however, once a company commits to a fixed publication schedule for its quarterly reports, for example by including Q1 and Q3 dates in its published financial calendar and reporting consistently on that basis. At that point the market and PDMRs come to rely on those dates in the same way as for the annual and half-year reports, and the company has, in substance, made itself obliged to publish on that timetable.

Issuers should build the 30 day closed period into their financial calendar and PDMR communications well in advance, since it affects not only PDMRs' own dealings but also their ability to grant or exercise instruments such as warrants during that window, absent an applicable exemption. Note that the company can choose to have a longer, but not a shorter, closed period than the mandatory 30 days. Any longer period should be specified in the company's internal rules.

Content requirements and deadlines

Under the Nasdaq First North Growth Market Rulebook, First North issuers are required to publish a half-year report. There is no obligation to publish a quarterly report.

Since 1 August 2022, the rules on financial reports for First North Copenhagen issuers have been relaxed, and Danish issuers are exempt from the Rulebook's general provisions on financial reports in sections 4.3 and 4.4. As a result, there are very limited requirements as to what content a quarterly, half-year or annual report must contain.

Nasdaq's requirements for financial reports in Denmark, Rulebook Supplement D

4.2.1(a)
The issuer must attach the annual report and the half-year report to the company announcement that is published. It is not sufficient to merely insert a hyperlink to the website.
4.3.1
The issuer shall publish a half-year report and an annual report.
4.3.2
If the issuer chooses to publish quarterly reports, the rules in 4.3.3 to 4.3.5 of the Rulebook apply accordingly.
4.3.3
All financial information shall be prepared in accordance with the accounting laws and regulations applicable to the issuer.
4.3.4
The issuer shall publish its annual report as soon as possible and no later than four months after the end of the financial year.
4.3.5
The issuer shall publish its half-year report as soon as possible and no later than three months after the end of the period.

There are, accordingly, no content requirements for the half-year report beyond following local accounting law and regulation, and the Danish Financial Statements Act does not contain any rules specifically addressing half-year reporting for First North companies.

Using the Danish Interim Report Regulation as a template

PwC recommends in the 2026 Stock Exchange Handbook (Børshåndbogen 2026) that First North issuers apply the requirements of the Danish Interim Report Regulation (Delårsbekendtgørelsen) as a template. The Interim Report Regulation applies in principle to companies on the main market and sets out requirements for the preparation of half-year reports. Many First North companies follow this template in practice. The Rulebook's general rules on half-year reporting, from which Danish issuers are exempt, closely mirror those requirements but additionally require two extra metrics: earnings per share, and the number of outstanding shares, per Rulebook 4.4.6.

NB: Danish issuers are exempt from all of the general half-year reporting requirements in Rulebook 4.4.6.

Danish Interim Report Regulation (PwC's recommendation)Rulebook 4.4.6, general rule from which Denmark is exempt
Management commentaryNot required
Management's statementNot required
Summarized income statement with comparativesa) Summarized income statement with comparatives
Summarized balance sheet with comparativesb) Summarized balance sheet with comparatives
Cash flow statement with comparativesc) Summarized cash flow statement with comparatives
Statement of changes in equity during the reporting periodd) Statement of changes in equity during the reporting period
Not requirede) Earnings per share with comparatives
Not requiredf) Number of outstanding shares
Explanation of the earnings trend and financial position in the most recent period, including the effect of significant extraordinary eventsg) Same
Follow-up on previously published guidanceh) Same

Timing and the official date of financial reports

Reports must be published immediately after the board has approved them in the board meeting, which means that publication shall not await subsequent electronic signature. In many cases, final edits or other outstanding matters may mean the report is not ready for publication the moment the board meeting concludes. In such situations it is best practice for the board to formally delegate authority to the executive management or the chairman to finalise and approve the report on behalf of the board, a procedure that is common in practice. This delegation must be correctly handled and properly recorded in the board minutes.

The official date stated in the financial report must always correspond to the actual date of publication. This rule applies even when the board meeting was held the day or evening before and the report was only finalised and ready for distribution the following morning. In such cases the official report date must reflect the morning of publication, not the date of the board meeting. This requirement ensures alignment between the board's formal approval of the final document and the date that investors receive the information.

ReportDeadline
Annual financial reportWithin 4 months after the end of the financial year
Half-yearly reportWithin 3 months after the end of the reporting period
Quarterly report, if the issuer chooses to publish oneWithin 3 months after the end of the reporting period

Managers' transactions

MAR Article 19

When your board members, executive management and certain other senior staff buy or sell your shares, options or warrants, those transactions become public. The obligation comes directly from Article 19 MAR, and it applies identically on First North and the Main Market. The individual notifies the issuer and the Danish FSA, and the issuer publishes a company announcement.

Who is a PDMR (person discharging managerial responsibilities)

  • A member of the board of directors or of executive management; or
  • A senior executive who is not on either body, but who has regular access to inside information relating directly or indirectly to the issuer, and has power to take managerial decisions affecting its future development and business prospects.

The second category is where most practical difficulty arises. It is not limited to C-suite titles. A COO or a divisional head with genuine decision-making authority and standing access to inside information can qualify on substance. Identify your PDMR population deliberately, write it down, and revisit it when roles change. HCA helps with that assessment.

Persons closely associated

The disclosure obligations that apply to PDMRs apply likewise to persons closely associated with PDMRs. Persons closely associated are:

  • A spouse or registered partner, and dependent children;
  • Other relatives who have shared the same household for at least one year on the relevant date; and
  • Any legal person, trust or partnership in which a PDMR, or one of the persons above, holds managerial responsibility, which is directly or indirectly controlled by them, which is set up for their benefit, or whose economic interests are substantially equivalent to theirs.

PDMRs must notify their closely associated persons in writing of these obligations and keep a copy of the notification. Do not assume this happens by itself. It is a documented step, and the document is the evidence.

The threshold, EUR 50,000 per calendar year

Notification is required once the total market value of a PDMR's transactions reaches EUR 50,000 within a calendar year. This is the threshold Denmark has set under Article 19(9). It is the market value of each transaction that counts, and transactions are aggregated without netting, so a purchase and a later sale both count towards the threshold rather than offsetting one another. Once the cumulative value across all transaction types is reached, every subsequent transaction in that calendar year is notifiable, including small ones.

What counts as a notifiable transaction

  • Purchases and sales of shares;
  • Acceptance or exercise of warrants and options, and disposal of shares received on exercise. See Warrant incentive programmes;
  • Pledging or lending financial instruments as collateral;
  • Gifts and donations of shares;
  • Transactions carried out by a third party, including a portfolio manager, on behalf of the PDMR where the PDMR gave instructions or otherwise directed the transaction.

Separately, PDMRs are in principle prohibited from dealing during closed periods, though Article 19(12) and (12a) carve out certain transactions from that prohibition. Check before relying on a carve-out.

Deadlines

  1. Within three business days

    The PDMR or closely associated person must notify the issuer and the Danish FSA as soon as possible and no later than three business days after the transaction date. There is no discretion to delay. The notification to the Danish FSA is made directly in the OAM system.

  2. Within two business days

    The issuer must make the information public no later than two business days after receiving the notification, counted from receipt and not from the transaction date.

In practice this means your own internal handling window can be very short if a PDMR notifies you on day three. Agree in advance who drafts and who releases, so that a holiday or a sick day does not become a breach.

It is the PDMR’s responsibility to report the transaction in the OAM system, but PDMRs often ask the company to handle the reporting on their behalf. Please note that, in order to do so, the company must hold a power of attorney from the PDMR, and that this power of attorney must be prepared and registered in the OAM system.

Closed periods

Separately from the notification obligation, PDMRs may not conduct transactions during the 30 calendar days before the announcement of an interim or year-end financial report. See Financial reports for how this applies to voluntary Q1 and Q3 reports.

What the announcement must contain

  • The identity of the PDMR or closely associated person;
  • Their position, or the reason they are a PDMR;
  • The issuer's name and LEI;
  • A description of the financial instrument;
  • The nature of the transaction, meaning acquisition, disposal, pledge and so on;
  • The date and place of the transaction; and
  • The price and volume.

Publish in the category Managers' Transactions. The Danish FSA has published guidance on reporting in OAM.

If you are a PDMR

Written for the individual. Hand this to a new board member or executive

This page is addressed to you personally rather than to the company. If you sit on the board or in executive management of a company HCA acts for, the obligations below are yours, not the company’s, and you carry them yourself. They also apply to you if you are a senior executive who is not on either body but who has regular access to inside information and the power to take managerial decisions affecting the company’s future development.

There are four things to get right, and one rule that overrides all of them.

  1. Tell your closely associated persons, in writing

    Their transactions in the company’s shares count as yours for notification purposes. The category covers your spouse or registered partner, your dependent children, any other relative who has shared your household for at least a year, and any company, trust or partnership that you control, that you manage, that is set up for your benefit, or whose economic interests are substantially the same as yours.

    You must notify them in writing of these obligations, and keep a copy of that notification. Do not assume it has happened because it was mentioned at a board meeting. The document is the evidence.

  2. Know when the EUR 50,000 clock has started

    Your transactions become notifiable once their total market value reaches EUR 50,000 within a calendar year. Transactions are aggregated without netting, so a purchase and a later sale both count towards the threshold rather than cancelling each other out. Once you cross it, every further transaction in that calendar year is notifiable, including small ones. The count resets on 1 January.

  3. Notify within three business days

    You notify both the company and the Danish FSA, the latter directly in the OAM system, as soon as possible and no later than three business days after the transaction date. There is no discretion to delay and no convenience exception. The company then has two business days from receiving your notification to publish it, so a notification that arrives on your third day leaves them very little room.

    The Danish FSA has published guidance on reporting in OAM.

  4. Do not deal in a closed period

    You may not deal in the company’s shares or debt instruments during the 30 calendar days before the announcement of an interim or year-end report, on your own account or for anyone else, directly or indirectly. This covers the annual report and the half-year report, and in HCA’s view any quarterly report published on a fixed calendared schedule. Certain transactions are carved out under Article 19(12) and (12a), but check before relying on a carve-out rather than after.

    Work out the exact dates with the closed period calculator, and note that the period runs right up to the moment the report is published.

What counts as a transaction

More than buying and selling shares. The list includes:

  • purchases and sales of shares;
  • accepting or exercising warrants and options, including those granted as part of your remuneration, and selling the shares you receive on exercise;
  • pledging or lending financial instruments as collateral;
  • gifts and donations, made or received; and
  • transactions a portfolio manager or other third party carries out on your behalf where you gave the instruction or otherwise directed it.

A discretionary mandate does not remove the obligation if you directed the trade. See Managers’ transactions for the company-side detail and the full content requirements for the announcement.

The information that you need

  • The transaction date, the instrument, the nature of the transaction, the place, the price and the volume.
  • Your position, or the reason you are treated as a PDMR.
  • Whether the transaction was yours or a closely associated person’s, and if the latter, whose.

If you think you have got something wrong

Tell the company immediately, and tell HCA. A notification that is late and disclosed is a smaller problem than one that is late and quiet, and the sequence of events is much easier to explain while it is still recent. The same applies if you are unsure whether something you know counts as inside information. Ask before you act, not after.

Share buybacks

MAR Articles 5, 14 and 15, Delegated Regulation (EU) 2016/1052

A share buyback is a company repurchasing its own shares, because management sees no better use for surplus cash, to support the share price, to return capital, or to fund an incentive programme. As your Certified Adviser, HCA helps plan and run a compliant programme. The summary below is the framework HCA works within.

The risk you are managing

The key legal risk in any share buyback is breaching the prohibitions on insider dealing and market manipulation in Articles 14 and 15 MAR. A company buying its own shares is, by definition, a buyer with better information than the market.

The Article 5 safe harbour

Article 5 MAR provides a safe harbour: a share buyback conducted in compliance with conditions on transparency, purpose, price and volume proceeds without the Article 14 and 15 prohibitions applying to it. The conditions are cumulative and must be satisfied throughout, not on average.

Purpose
The programme must pursue one of the permitted purposes: reducing capital, meeting obligations from debt instruments convertible into equity, or meeting obligations under employee share or other allocation programmes.
Full public disclosure before trading starts
The programme must be disclosed in adequate detail before dealing begins, covering purpose, maximum consideration, maximum number of shares and duration.
Reporting and publication
Every transaction must be reported to the competent authority of the venue with the highest liquidity in the share and made public, including on your own website, no later than the end of the seventh daily trading session after the transaction date, per Articles 5(1)(b) and 5(3) MAR as amended by the Listing Act.
Price limit
No purchases above the higher of the last independent trade price and the highest current independent bid on the venue.
Volume limit
No more than 25 per cent of the average daily volume on the venue, calculated on the applicable reference period.
Trading conditions and restrictions
Purchases must be made on the venue where the shares are admitted to trading. During the life of the programme you must not sell your own shares, trade during a closed period, or trade while in possession of inside information, per Articles 3(1) and 4(1) of Delegated Regulation (EU) 2016/1052. These restrictions do not apply, however, where (a) the programme is time-scheduled, meaning purchases are executed according to a schedule announced in advance, without any discretion as to timing, or (b) the programme is lead-managed by an investment firm or credit institution which makes its trading decisions concerning the timing of the purchases independently of the issuer, per Article 4(2) of Delegated Regulation (EU) 2016/1052.

Listing Act simplifications already in force

  • Single-authority reporting. You now report share buyback transactions only to the competent authority of the trading venue with the highest liquidity in the share, rather than to every venue's authority.
  • Aggregate public disclosure. You may publish aggregate daily trading information, meaning total volume and volume-weighted average price per venue, instead of every individual trade.

If the safe harbour does not apply

A share buyback conducted without relying on, or without qualifying for, the safe harbour is not automatically market abuse. Recital 12 MAR is clear on that. But you lose the protection and must take particular care: no dealing while holding inside information, no conduct that gives false or misleading signals, and a documented assessment of why the programme is legitimate. Decide up front which route you are taking, because the safe harbour conditions have to be satisfied from the outset and cannot be retrofitted.

Is the decision to launch a share buyback inside information?

A recurring question: should the launch of a programme be classified as inside information, or treated simply as an acquisition of own shares, for example where the general meeting has already authorised the board? The answer turns on the Article 7(1)(a) test. Would the information be likely to have a significant effect on the price, in the sense that a reasonable investor would use it as part of the basis of an investment decision? For most First North companies, where a share buyback is a departure from prior capital allocation, the answer is usually yes. Make the assessment, document it, and make it before the decision is taken rather than in the hours after.

Danish FSA guidance on handling share buybacks

The FSA has observed that trading activity often increases both before and after the launch of a programme. An increase afterwards is expected. An increase beforehand is a red flag, and the FSA has seen cases of employees of listed companies trading ahead of a share buyback announcement. It has highlighted three points.

Classification
The launch must be disclosed in accordance with MAR, and companies should assess and handle its classification as inside information in good time, not retrospectively.
Framework agreements
Some companies have framework agreements with financial intermediaries allowing a programme to be initiated quickly, typically within one to two weeks. In such cases inside information can arise very early, and the insider list and confidentiality controls need to be in place from that point.
Employee trading
Because the share price typically rises after announcement, companies should ensure employees understand that trading ahead of a programme they know about is insider dealing. Note that share buybacks are often announced alongside financial reporting, that is, during closed periods, which reduces but does not eliminate the risk.

Prospectus requirements

Prospectus Regulation (EU) 2017/1129, as amended

When does a First North company need to publish a prospectus under the EU Prospectus Regulation? Less often than most issuers assume, but the exemptions have conditions, and the conditions have changed.

The starting point, First North is not a regulated market

The Prospectus Regulation's admission-to-trading trigger applies to regulated markets only. Nasdaq First North Copenhagen is a multilateral trading facility, so admission to trading on First North does not by itself trigger a prospectus obligation. What can trigger it is an offer of securities to the public. The Nasdaq First North Rulebook applies instead at admission, with its own company description requirements.

What the EU Listing Act changed

Amendments to the Prospectus Regulation entered into force on 5 June 2026, following earlier changes on 4 December 2024. Together they are the most relevant reference point for First North issuers planning a raise.

Exemption threshold raised
Public offers below EUR 12 million per issuer over 12 months are exempt, up from EUR 8 million. Denmark applies the general EUR 12 million threshold.
The EUR 1 million floor is gone
The rule under which offers below EUR 1 million fell outside the Regulation entirely no longer applies from 5 June 2026. There is now a single relevant threshold.
Fungibility threshold raised from 20 to 30 per cent
Effective since December 2024, with a further exemption for issuers admitted to trading continuously for at least 18 months.
Simplified content and format
New standardised EU prospectus formats have applied since 5 June 2026, and audited financial history in equity prospectuses is reduced from three years to two.

When is a prospectus required? Main scenarios

The table below sets out the position for companies on Nasdaq First North Copenhagen as it stands following the 5 June 2026 amendments. PR in the table is short for Regulation (EU) 2017/1129, the Prospectus Regulation.

ScenarioProspectus?Basis / condition
Public offer below EUR 12m over 12 monthsNo, exemptArt. 3(2) PR as amended by Listing Act (EU) 2024/2809
Public offer above EUR 12mYes, unless an Art. 1(4) exemption appliesExemptions include offers solely to qualified investors, offers to fewer than 150 non-qualified investors per Member State, and minimum-denomination offers, per Art. 1(4) PR
Initial admission to First North (IPO)No EU prospectusPR applies to regulated markets only and First North is an MTF. Rulebook company description applies instead, per Art. 1(1) and Recital 14 PR
Follow-on issue of fungible shares, issuer admitted 18 months or moreNoArt. 1(4)(j) and 1(5) PR as amended
Follow-on issue of fungible shares below 30 per cent of the class, issuer admitted less than 18 monthsNoArt. 1(5)(a) PR as amended
Shares from conversion or exercise of warrants or convertiblesNoExempt if fungible with an admitted class, per Art. 1(5)(b) PR
Employee or director sharesNoAn information document must be made available, per Art. 1(5)(h) PR
Merger or divisionNoA document describing the transaction must be made available, per Art. 1(5)(e) PR
Takeover by exchange offerNoA document describing the transaction and its impact must be made available, per Art. 1(5)(f) PR

For the fungible-shares exemptions under Art. 1(4)(da) and (db) and Art. 1(5) PR, meaning the sub-30 per cent and 18-month continuous-admission routes, it is sufficient that a short-form disclosure document containing the information set out in Annex IX PR is filed electronically with the competent authority and made available to the public at the same time, without requiring the competent authority’s approval.

Your capital situation

Danish Companies Act §§ 118 and 119, Rulebook 2.3.6, 4.2.1(c) and 4.2.5(a), MAR Article 17

Maintaining sufficient capital and liquidity is not only sound management. It is a legal duty under Danish company law, and a recurring source of Rulebook and MAR disclosure obligations. This section follows the capital lifecycle and flags where an announcement, a general meeting, or some other action is required.

Three rule sets working together

Danish Companies Act § 118
The executive board must ensure at all times that the company's financial resources are adequate and that it has sufficient liquidity to meet current and future liabilities as they fall due.
Danish Companies Act § 119
A general meeting must be held within six months of it being established that equity represents less than half of the subscribed share capital. Management must report on the financial position and, if necessary, propose measures.
The First North Rulebook
Sufficient working capital for at least 12 months at admission (section 2.3.6); the obligation to correct the market's perception where previously disclosed information no longer holds (section 4.2.1(c)); and disclosure of specific capital events, including conversion of convertible loans (section 4.2.5(a)).
MAR Article 17
Where information about your capital situation is precise, not public, and likely to have a significant price effect, it must be disclosed as soon as possible.

Step 1, continuous assessment

Unlike a one-off event, the capital situation is monitored continuously. Section 118 makes this an explicit management duty. And although the Rulebook's working capital requirement is worded as an admission condition, in practice it operates as a continuing obligation to assess whether you have, and will continue to have, 12 months of working capital.

The assessment should specifically consider whether there is significant uncertainty about continued operations, and whether that uncertainty itself amounts to inside information. Nasdaq may assign observation status where it identifies significant uncertainty about continued operations, and your Certified Adviser is separately required to confirm to Nasdaq, in its annual report, that the company has sufficient working capital. That confirmation cannot be given on optimism, so bring HCA into the assessment early. The assessment itself does not require an announcement. Its findings feed directly into the steps below.

Step 2, funding for the next 12 months is not secured

Whether this triggers disclosure depends entirely on what you have already told the market.

No contradictory prior statements
There is no general obligation to disclose that funding for the next 12 months is not yet fully secured, provided you have not given the market a contrary impression.
Contradictory prior statements
Where you have previously given a different impression of your capital position, you must correct that perception as soon as possible after becoming aware of the changed situation.

Separately, and regardless of any disclosure obligation, § 118 obliges the board to consider and plan how the company will be funded over the next 12 months. The absence of a disclosure duty is not the absence of a duty.

Step 3, cash runs out earlier than guided, or guidance turns out wrong

There is no general obligation to give guidance, on revenue, EBITDA, cash position or anything else. But once given, guidance that turns out to be misleading must be corrected. Where guidance or previously disclosed information about your cash runway proves incorrect, you must disclose correct information as soon as you become aware, under Rulebook section 4.2.1(c).

An announcement correcting or adjusting previously disclosed information should restate the earlier information, so investors can evaluate the significance of the change. This obligation applies whether or not the information qualifies as inside information, since it follows directly from 4.2.1(c). Where it also qualifies as inside information, the MAR timing and handling rules apply on top.

Step 4, raising capital through loans, convertibles and share issues

The central question is when plans or considerations about financing cross into inside information.

Rights issues and directed issues
A decision to raise capital through a rights issue or directed issue will generally be inside information and must be disclosed immediately after the board decides to call the general meeting or to exercise its authorisation.
Once the issue is completed
Two announcements must be made: the result of the issue, in the category Inside information, and the change in the number of voting rights and capital, in the category Total number of voting rights and capital.
Timing can precede the formal decision
The Danish FSA's 2025 decision concerning BactiQuant A/S confirms that inside information about a capital need, and separately about the specific issue used to meet it, can arise before the formal board resolution. Waiting for the minutes is not a safe harbour.
Bank and shareholder loans
A decision to take up a loan may or may not be inside information, on a concrete assessment of size and terms. Business-as-usual financing on ordinary terms generally is not.
Convertible loans
Conversion must be disclosed under Rulebook section 4.2.5(a).

You may postpone disclosure of inside information at your own risk provided the Article 17(4) conditions are met, including that immediate disclosure would be likely to prejudice your legitimate interests. Ongoing financing negotiations are a recognised example, but the delay ends the moment confidentiality is lost or the withheld information becomes inconsistent with what you have already said. See Inside information under MAR and Prospectus requirements.

From a practical perspective, please be reminded that your Certified Adviser, or legal adviser, must be notified about the capital increase in due time to be able to submit an application via Nasdaq’s Listing Center for the additional shares to be admitted to trading as soon as possible after the shares have been issued. The application must include all relevant details of the capital increase, including a copy of the updated Articles of Association and documentation that the capital increase has been registered with the Danish Business Authority (“Sagsresume”).

Step 5, loss of share capital

Where equity falls below half of the subscribed share capital, § 119 requires management to ensure a general meeting is held no later than six months after this is established. At that meeting management must report on the financial position and, if necessary, propose measures, including where relevant a proposal to dissolve the company. For this purpose the comparator is the registered nominal share capital, not market value.

The risk of failing to act under §§ 118 and 119 is ultimately personal: management can face personal liability and compensation claims. Companies that monitor capital continuously, rather than reacting when cash becomes critical, are in a far better position on both counts.

Warrant incentive programmes

MAR Articles 17 and 19, Rulebook requirements on warrant and option programmes

Warrant-based incentive programmes are a common way to align management and key employees with shareholders. Adopting and running one triggers a sequence of disclosure obligations, under MAR Article 17, under the Rulebook's specific requirements for decisions on warrant and option programmes, and under Article 19 for the individuals receiving the instruments. This section follows the lifecycle and flags where an announcement is generally required.

  1. The general meeting authorises the board

    Most programmes start with a general meeting resolution either to issue warrants directly to named recipients, or to authorise the board to issue warrants within a defined framework, covering maximum number of warrants and shares, exercise price mechanism, recipient categories and exercise period, at its own discretion and typically for future use.

    The resolution, including the scope of any authorisation granted to the board, is disclosed as part of the standard announcement of resolutions passed at the general meeting, in the category Decisions of general meeting / Forløb af generalforsamling. At this stage no separate announcement is normally required.

  2. The board resolves to use the authorisation

    When the board later decides to actually use its authorisation and adopt a concrete programme, that is normally a separate, standalone disclosure event. The decision typically specifies the total number of warrants to be issued, the exercise price and the method used to determine it, the vesting and exercise conditions and the exercise windows, and the recipient group, meaning management, board or key employees, and where relevant the maximum dilutive effect.

    This falls squarely within the Rulebook's specific disclosure requirements for decisions on warrant and option programmes, and shall be announced in the category Other information disclosed according to the rules of the Exchange unless it qualifies as inside information under Article 17 in case of a significant effect on dilution and remuneration, in which case it should be disclosed as inside information.

  3. Warrants are granted, conditionally or unconditionally

    The actual allotment to named recipients is a distinct step from the board's decision to adopt the programme, and generates its own obligations.

    Conditional grants. Where warrants are granted subject to conditions precedent, such as continued employment at a future date, individual or company performance targets, or subsequent ratification, the grant is not yet an unconditional instrument in the recipient's hands, and the PDMR notification obligation is generally not yet triggered. However, it may still be prudent to make a first PDMR notification clearly stating that the grant is conditional.

    Unconditional grants. Once the conditions are satisfied, or where the grant was unconditional from the outset, the warrant becomes an unconditional financial instrument. If the recipient is a PDMR or a closely associated person, the Article 19 analysis applies, and PDMR notifications must be made.

    PDMR notifications on grants. Grants and exercises of share options as part of a remuneration package are explicitly among the transaction types PDMRs must notify under Article 19 and the related delegated regulation. Once the EUR 50,000 aggregate threshold is crossed in the calendar year, the PDMR must notify the Danish FSA via the OAM system, and the company, as soon as possible and no later than three business days after the transaction. The company must then publish a company announcement as soon as possible and no later than two business days after receiving the PDMR's notification, in the category Managers' Transactions / Ledende medarbejderes transaktioner.

  4. Warrants are exercised

    When warrants are exercised and new shares are subscribed for, two separate obligations typically arise.

    Capital increase announcement. You must announce the resulting increase in share capital and the new total number of shares and votes, under the Rulebook's requirements for changes to share capital, in the category Total number of voting rights and capital / Antal stemmerettigheder og kapital.

    Admission of the new shares. Please also be reminded that your Certified Adviser, or legal adviser, must be notified in due time to be able to submit an application via Nasdaq’s Listing Center for the additional shares to be admitted to trading as soon as possible after the warrants have been exercised. The application must include all relevant details of the capital increase, including a copy of the updated Articles of Association and documentation that the capital increase has been registered with the Danish Business Authority (“Sagsresume”).

    PDMR transaction notification, where applicable. If the exercising holder is a PDMR or a closely associated person, the exercise and the subsequent subscription of shares is a notifiable transaction. See Managers' transactions.

Information on the website

Rulebook 4.6

Rulebook 4.6 requires every First North company to maintain its own website and to keep a defined set of information available there. The rule has two parts: an archive obligation for everything you disclose, under 4.6.1 and 4.6.2, and a standing-information obligation covering your Articles of Association, financial calendar, Certified Adviser details and board and management profiles, under 4.6.3. Nasdaq checks compliance on an ongoing basis, and as your Certified Adviser, HCA reviews the investor section of your site periodically.

4.6.1 An identifiable investor section, with a five-year archive

The company must have its own website on which all information disclosed under the Rulebook is available for at least five years. Investors must be able to find that information in an easily identifiable section of the site.

In practice this means a dedicated investor relations area, reachable from the front page, with announcements listed in reverse chronological order and no material removed before the five-year point. Announcements should not be limited to the current year, and links from news items to attachments must not be allowed to break when the site is redesigned.

4.6.2 Financial reports, prospectuses and direct links

Financial reports and other information provided for distribution to shareholders must remain available on the website for at least five years. For prospectuses and the Company Description the retention period is at least ten years.

The same periods apply to links. A direct link included in the original announcement to the page on the company's website where the financial report is available must stay valid for at least five years, and at least ten years for prospectuses and the Company Description. A website migration that changes URL paths is the most common cause of a breach here, so redirects must be put in place before the old links stop working.

4.6.3 Standing company information

In addition to the disclosure archive, the website must include the company's Articles of Association, the company calendar per section 4.5, and the name and contact details of the Certified Adviser. It must also present details of the current Board of Directors and Senior Management, covering for each person:

  • position with the company and other significant positions;
  • education and experience;
  • shares and other financial instruments issued by the company held by that person and/or closely related parties;
  • information on the dependency or independence of directors, in relation to the company, Senior Management and major shareholders; and
  • the year in which the position commenced.

The information must be kept current. Changes to the board or management following a general meeting, and changes in holdings, should be reflected on the site at the same time as they are announced.

For the purpose of this rule, independence is defined in the same way as in the corporate governance code of the jurisdiction where the company's financial instruments are admitted to trading, or, where the company applies an equivalent code in its country of incorporation, that code. For companies on First North Growth Market Denmark, this means the Recommendations on Corporate Governance issued by the Danish Committee on Corporate Governance.

The independence criteria, Recommendation 3.2.1

According to the Danish Committee on Corporate Governance, the criteria for independence are set out in Recommendation 3.2.1. A board member is not considered independent if that person:

  • is, or within the past 5 years has been, a member of the executive management or a senior employee of the company, a subsidiary or an associated company;
  • has, within the past 5 years, received significant remuneration from the company or group in a capacity other than as a board member, including as an adviser;
  • represents or is closely connected to a controlling shareholder;
  • has, within the past year, had a material business relationship with the company, directly or indirectly, for example as a partner, employee, shareholder, customer, supplier or member of management of a party to such a relationship;
  • is, or within the past 3 years has been, an employee or partner of the company's auditor elected by the general meeting;
  • is an executive of a company that has cross-directorships with the company;
  • has been a board member for more than 12 years; or
  • is a close relative of persons who are not considered independent under the above.

The board may furthermore, on other grounds, assess that a member is not independent. The list is therefore not exhaustive, and the assessment must be made on a case-by-case basis. Close relatives means spouses, relatives in the ascending and descending line, siblings, the spouses of the aforementioned persons, and other persons who have been particularly close to one another. In the Committee's view, employee representatives are not independent.

What counts as a controlling shareholder

The Recommendations do not operate with a fixed, legal definition of a controlling shareholder in the same way as the concept of controlling influence under the Danish Companies Act. Instead, the Committee provides a guiding rule of thumb in the commentary to Recommendation 3.2.1: a shareholder holding more than 20 per cent of the voting rights is, as a starting point, considered to have significant influence.

This is precisely a starting point and not an absolute threshold. The assessment is made on a case-by-case basis, and control or significant influence may exist below 20 per cent, for example if the shareholder is in practice able to enforce its will at the general meeting due to low attendance, shareholder agreements, the right to appoint board members or other special rights.

The fact that a board member is elected with the votes of a controlling shareholder does not in itself mean that the board member is dependent. If several board members are connected to shareholders with significant influence, the board should consider whether the composition is appropriate in relation to independence. The purpose of the criterion is to ensure that board members who represent or are closely connected to such a shareholder are not counted as independent, because they may have an interest in serving the special interests of the majority shareholder rather than the overall interests of the company and the minority shareholders.

By way of comparison, the Danish Companies Act section 7 uses the concept of controlling influence, which typically exists where a party holds more than 50 per cent of the voting rights, or where it can in fact exercise controlling influence in another way. The Committee's 20 per cent threshold is thus a lower and broader threshold, aimed specifically at the independence assessment.

Source: Recommendations on Corporate Governance, the Danish Committee on Corporate Governance

Regulatory news

What is changing, and when

This section is maintained by HCA, and it is the one place in the portal you should check before assuming last year's procedure still holds.

  1. 5 June 2026

    EU Listing Act, final changes

    The last Regulation (EU) 2024/2809 amendments apply. Intermediate steps in a protracted process are no longer separately disclosable as inside information. The Article 17(4) condition (b) is reformulated as a not inconsistent test. The prospectus exemption threshold is raised to EUR 12 million and the EUR 1 million lower limit falls away, new standardised prospectus formats apply, and audited financial history is reduced from three years to two. See Inside information under MAR and Prospectus requirements.

  2. 5 March 2026

    Two new prospectus types

    The EU Follow-on prospectus replaces the simplified regime for secondary issuances, and the EU Growth issuance prospectus replaces the EU Growth prospectus. See Prospectus requirements.

  3. 1 July 2025

    Managers’ transactions threshold raised to EUR 50,000

    The Danish FSA raised the threshold for notifying managers’ transactions to EUR 50,000 per calendar year. See Managers' transactions.

  4. 27 June 2025

    Method of disclosing inside information

    Danish FSA capital markets newsletter restating the Implementing Regulation 2016/1055 requirements for how an announcement must be made. The announcement itself must state that it contains inside information. The Nasdaq category alone is not enough. See Inside information under MAR.

  5. 18 June 2025

    When inside information about a capital need arises

    Danish FSA reprimand of BactiQuant A/S. Information about the capital need, and about the planned rights issue, was inside information from the board meeting on 18 December 2024, weeks before the announcement on 7 January 2025 and ahead of the formal resolution. See Your capital situation.

  6. 4 December 2024

    EU Listing Act, first changes

    The Listing Act enters into force. The prospectus exemption for fungible shares is raised from 20 to 30 per cent, and issuers admitted for at least 18 months get a new exemption. See Prospectus requirements.

Closed periods

MAR Article 19(11), at least 30 calendar days before an interim or year-end report

Under Article 19(11) a PDMR must not deal in your shares or debt instruments, on their own account or for a third party, during the 30 calendar days before the announcement of an interim or year-end financial report. Many companies set a longer closed period in their internal rules. The arithmetic is simple, but it is done by hand often enough, and by enough different people, that it is worth having in one place.

Enter the dates from your financial calendar, and the length of the closed period in your internal rules if it is longer than 30 days. The calculator returns each closed window, and will tell you whether a particular date falls inside one.

Closed period calculator

Nothing entered here is saved, stored or sent anywhere. It is arithmetic in your browser.

How the window is calculated

Thirty calendar days, or the longer period in your internal rules, counted back from the day the report is announced. Weekends and public holidays are inside the count, so there is no business day arithmetic to do. A report published on 15 March closes the window from 13 February, and dealing is possible again only once the report is out.

That last point is worth stating plainly, because it is where the day count is usually misread. The period runs to the moment of publication, not to the end of the previous day. The publication date itself is closed until the announcement has been released.

What the calculator assumes

  • Thirty calendar days unless you enter a longer period. Thirty is the statutory minimum: a company may set a longer period in its internal rules but never a shorter one, so the calculator will not go below it.
  • The window runs to the moment the report is published, so the publication day is treated as closed.
  • Quarterly reports count. A Q1 or Q3 report published on a fixed, calendared schedule should be treated as triggering the period, for the reasons set out in Financial reports.

What it does not cover

  • The carve-outs in Article 19(12) and (12a), which exempt certain transactions from the prohibition. Check before relying on one.
  • Grant and exercise dates under a warrant programme, which need checking against the same calendar. See Warrant incentive programmes.
  • Changes to the financial calendar. A date moved within 14 days of the event needs its own announcement, and it moves the closed period with it.
  • Any restriction in a shareholder agreement or lock-up, or any rule in your internal dealing policy other than the length of the closed period.

Build the windows into the financial calendar and tell PDMRs about them well in advance. The 30 days affect not only their own dealings but their ability to accept or exercise instruments during that period, absent an applicable exemption.

Delay decision record

MAR Article 17(4), the record you create when you decide to delay

You may delay disclosure of inside information on your own responsibility, provided the three conditions in Article 17(4) are met and remain met. Under the Danish approach you are not required to submit a written explanation of the legitimate interest unless the FSA asks for it. That is precisely why the record matters: if you are asked, months later, the contemporaneous note is what you will rely on, and reconstructing your reasoning after the event is not the same thing.

This builder assembles that note. Fill in what you know, copy the result into your own file, and revisit it when the position changes. A delay decision is one you have to keep making, not one you make once.

Delay decision record

Nothing is saved, stored or sent. Close the tab and it is gone. What you type here is likely to be inside information, so keep the copy somewhere you control.

The record

Keep the decision under review

The three conditions have to hold throughout, not just at the moment you decided. If confidentiality is lost, or if the withheld information becomes inconsistent with something you have since told the market, the delay ends and you disclose immediately. Set the review date and actually use it.

When the information is finally published

You must notify the Danish FSA without delay that disclosure was delayed. The notification is made on the FSA’s own form, available in Danish and English, and First North issuers send it to udsaettelse@ftnet.dk. Keep this record with your copy of that notification. The background is set out in Inside information under MAR.

Nothing in this portal constitutes legal advice. The guidance here is general, and specific situations should be assessed on their facts, with legal advice where the assessment is finely balanced.